Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irritation Potential of ATx201 in Healthy Volunteers
NCT03301870Phase 1Completed
- Sponsor
- UNION therapeutics
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of niclosamide in atopic dermatitis (AD) (9 arms), sponsored by UNION therapeutics. Primary endpoint: Cumulative Irritation Scores at 21 days. Started Oct 2017; status: completed.
02
Drugs
niclosamide
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03301870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301870.